Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · TERMINATED

Staph aureus types 5 and 8 conjugate vaccine

Staphylococcal Infections, Chronic Kidney Failure

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT unsatisfactory efficacy data from preceding trial

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

unsatisfactory efficacy data from preceding trial

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2008-01-04. Registry source

WATCH · SUSPENDED

Stavudine

HIV Infections

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2005-06-24. Registry source

WATCH · SUSPENDED

Stavudine

HIV Infections

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2005-06-24. Registry source

WATCH · TERMINATED

STI571 and PEG INTRON

Chronic Myeloid Leukemia

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-08-03. Registry source

WATCH · TERMINATED

Subcutaneous immunotherapy - Recombinant birch pollen

Allergy

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-12-19. Registry source

WATCH · TERMINATED

Sulfadoxine Pyrimethamine

Malaria

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The study was terminated because of Early Treatment Failure in child.The justification for this decision are concerns about safety of children.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The study was terminated because of Early Treatment Failure in child.The justification for this decision are concerns about safety of children.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-08-10. Registry source

WATCH · WITHDRAWN

SUM-101

Malaria Fever

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Not enough resources

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Not enough resources

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-11. Registry source

WATCH · TERMINATED

sumanirole

Parkinson Disease

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-01-18. Registry source

WATCH · WITHDRAWN

Sustiva (efavirenz)

HIV Infection, Hepatitis C

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-07-27. Registry source

WATCH · WITHDRAWN

Symptomatic treatment (ibuprofen and acetaminophen)

Acute Uncomplicated Diverticulitis

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Study was never approved by the institutional review board.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Study was never approved by the institutional review board.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-08-31. Registry source

WATCH · TERMINATED

Synbiotic 2000

Surgical Wound Infection, Cystitis, Bacteremia, Pneumonia, Enterocolitis, Pseudomembranous

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Patients would not take product

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Patients would not take product

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-11-01. Registry source

WATCH · TERMINATED

Synvisc-One 48 MG in 6 ML Prefilled Syringe

Osteoarthritis, Knee

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The study has only enrolled 6 subjects in 6 months since study initiation. Potential participants are unwilling to participate in the study due to the randomziation...

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The study has only enrolled 6 subjects in 6 months since study initiation. Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-17. Registry source